

TENDER NO. BMSIC/DRUGS/18-12

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name M/S Modern Laboratories Total Number of Pages 1- 303 Submitted in bid documents

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft drawn in Favor of “Managing Director, Bihar Medical Services and Infrastructure Corporation Limited” payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	Yes	271	Yes	
2	3.(b)	Bidder are required to submit Earnest Money Deposit in the form of Demand Draft / Bank Guarantee drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna as follows:- Upto 5 drugs- Rs1,00,000/- (One Lakh only), for 6 to 10 drugs- Rs 2,00,000/- (Two Lakh only), for 11 to 20 drugs- Rs 3,00,000/-(Three Lakh only) and for More than 20 drugs Rs 5,00,000/- (Five Lakh only)	Yes	268-270	Yes	
3	3.(c)	Documentary evidence of the constitution of the company/ firm/ Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	42-50	Yes	
4	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	51	Yes	
5	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. Format to be used.	Yes	53-55	Yes	
6	3.(f)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	Yes	273-282	Yes	

Chander Kumar
15/11/23

124

for any three of last four Consecutive Assessment could be submitted (self-attested).	Yes	283-285	Yes	
bidder company should be submitted (self-attested).	Yes	300	Yes	
Sales Tax/VAT and GST registration of the bidder should be submitted (self-attested).	Yes	301-303	Yes	

Chandim Kumar
86
13/01/19
PM

TENDER NO. BMSIC/DRUGS/18-12

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name M/s Modern Laboratories. Total Number of Pages Submitted in bid documents- 1 to 304

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	159	Yes	
2	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. Format to be used.	Yes	53 to 55 185 to 187	Yes	
3		Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate.	Yes	59 to 67 190 to 222	Yes	
4		Approved product list as per the license issued for quoted drugs for minimum three years.	Yes	254 to 258 68 to 91 199 to 222 241 to 142	Yes	
5		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	59 - 67 190-222 254-258, 68- 91 199-222 241-142	Yes	
6		In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.	Yes	223	Yes	

Ashley Gada
19/01/19

B. Kumar
19-01-2019

Prasanna
19.01.19

7	3.(f)	Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation).	Yes	170-171 225-258 100-126	Yes	
8		If permission in Form 46 (For manufacturers) / Form 45 (For Importers) from DCGI has been obtained, then the 3 years manufacturing/ Import & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.	-	-	-	
9		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCGI (I) shall be required for all new regulated products to this effect.	-	-	-	
10		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable	-	-	-	
		NOTE: Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	-	-	-	
11	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	

Nilay Bala
19/01/19

B Kumar
19-01-2019

Dendulnery
19.01.19

12	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	Yes	100-126 170-171 225-258	Yes	
13	3.(i)	Non Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted. It should be not more than one year old. Self-attested copies are to be submitted. For Surgicals In case of Non-Drug item "the bidder shall submit an affidavit on Non-Judicial stamp paper stating that the quoted product is not covered under Drugs & Cosmetics Act."	Yes	130-131 259-260	Yes	

Milky Boda
19/01/19

Bikumar
19-01-2019

Shondhony
19.01.19

14	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. Self-attested copies are to be submitted.	Yes	132-133 261-262	Yes	
15	3.(k)	Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section. Self-attested copies are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production(Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	Yes	98-99 134-263	Yes	
16	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.	Yes	135-136 264-265 266-267	Yes	
17	3.(o)	List of item quoted in prescribed format as per Annexure-III duly signed.	Yes	57-58 188-189	Yes	
18	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV.	Yes	157	Yes	
19	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	38-40 160-162	Yes	
20	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	53-55 185-187	Yes	

Nitish Bala

19/01/19

Prakash

19-01-2019

Prakash

19.01.19

21	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	-	-	-	
22	2 (d)	A Notarized affidavit on a Rs 100/- Non-Judicial Stamp Paper representing that the offered price is the lowest price as compared to the Rates provided to their respective Distributors/ Dealers/ Wholesalers/ Carrying and Forwarding Agents/ Authorized depot sales point in the State of Bihar.	Yes	158 166	Yes	

Omika Bada
 19/01/19

B Kumar
 19-01-2019

D. S. Mondal
 19.01.19

TENDER NO. BMSIC/DRUGS/18-12

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name: **M/s Modern Laboratories.** Total number of pages submitted in bid documents: 1 to 304

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic	
1	1	Lignocaine Hydrochloride Injection	Lignocaine Injection IP	2% w/v	Each ml Contains Lignocaine Hydrochloride IP 20 mg	30 ml vial	Not Mentioned	Injection	Injection	18.02.2015	31.12.2021	Generic	Yes
2	2	Tramadol Hydrochloride Injection	Tramadol Injection	50 mg/ml	Each 2 ml Contains Tramadol Hydrochloride IP 100 mg	2ml Amp.	Not Mentioned	Injection	Injection	18.02.2015	31.12.2021	Generic	Yes
3	3	Calcium Gluconate Injection	Calcium Gluconate Injection IP	100 mg/ ml	Each ml Contains calcium Gluconate IP 100 mg	10 ml vial	Not Mentioned	Injection	Injection	18.02.2015	31.12.2021	Generic	Yes
4	4	Albendazole Oral Suspension	Albendazole Oral Suspension IP/USP	200 mg/ 5 ml	Each 5 ml Contains Albendazole IP 200 mg	10 ml Bottle	Not Mentioned	Suspension	Suspension	18.02.2015	31.12.2021	Generic	Yes
5	5	Ampicillin and Cloxacillin Injection	Ampicillin and Cloxacillin Injection	Each vial Contains Ampicillin-250 mg and Cloxacillin-250 mg	Each vial contain Ampicillin Sodium IP equivalent to Ampicillin 250mg Cloxacillin Sodium IP equivalent to Cloxacillin 250mg	Vial	Viials	Injection	Injection	18.02.2015	31.12.2021	Generic	Yes

Milly Bala
19/01/19

B Kumar
19-01-2019

Pranav
19.01.19

6	6	Cefotaxime Sodium Injection	Cefotaxime Sodium Injection IP/ USP	500 mg	Each vial contains. Cefotaxime Sodium IP Equivalent to Cefotaxime 500mg	Vial	Vials	Injection	Injection	18.02.2015	31.12.2021	Generic	Yes
7	8	Meropenem Injection	Meropenem Injection IP	1000 mg	Each Vial Contains meropenem 1000 mg	Vial	Vials	Injection	Injection	18.02.2015	31.12.2021	Generic	Yes
8	9	Chloroquine Phosphate Syrup	Chloroquine Syrup IP Oral liquid	50 mg/5 ml	Each 5 ml Contains Chloroquine phosphate IP 80 mg Eq. to Chloroquine IP 50 mg. Syrup Base IP Qs.	60 ml Bottle	Not Mentioned	Syrup	Syrup	18.02.2015	31.12.2021	Generic	Yes
9	11	Ondansetron Hydrochloride Injection	Ondansetron Injection IP	2 mg/ ml	Each ml Contains Ondansetron Hydrochloride IP Eq. to Ondansetron 2 mg	2 ml Amp	Not Mentioned	Injection	Injection	18.02.2015	31.12.2021	Generic	Yes
10	12	Ranitidine Tablets	Ranitidine Tablets IP Oral Solid Dosage tab. Film Coated	150 mg	Each film Coated tablet Ranitidine Hydrochloride Eq. to Ranitidine IP 150 mg.	10 x 10	Not Mentioned	Tablets	Tablets	18.02.2015	31.12.2021	Generic	Yes

Atulya Patel
19/01/19

Pranav
19-01-2019

Pranav
19.01.19

11	18	Antacid Tablets	Dried Aluminium Hydroxide Gel magnesium Hydroxide tab. Antacid tab.	Tablet Containing: Dried Aluminium Hydroxide Gel- 250 mg Magnesium Hydroxide- 250mg, Activated Dimethicon 50mg	Each Uncoated tab. Contains Dried Aluminium Hydroxide 250 mg Magnesium Hydroxide IP 50 mg Activated Dimethicone IP 50 mg.	10 x 10	Not Mentioned	Tablets	Tablets	18.02.2015	31.12.2021	Generic	Yes
12	22	Calcium Tablets	Calcium Carbonate with vitamin D3 tab.	Each tablet Contains: Calcium Carbonate equivalent to 500mg elemental calcium and Vitamin D3-250 I.U	Each tablet Contains Calcium Carbonate Eq. to 500 mg elemental Calcium and vitamin D3 250 IU.	10 x 10	Not Mentioned	Tablets	Tablets	18.02.2015	31.12.2021	Generic	Yes
13	23	Atropine Injection	Atropine Salphate Injection IP	600µg/ml	Each ml Contains Atropine Sulphate IP 0.5 mg.	Ampules	Ampules	Injection	Injection	18.02.2015	31.12.2021	Generic	Yes

Nitya Bada
19/01/19

Edkumar
19-01-2019

Pranav
19/01/19

TENDER NO. BMSIC/DRUGS/18-12

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name: M/s Modern Laboratories. Total number of pages submitted in bid documents: 1 to 304

Sheet for verification of licence details

Sl. No	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	1	Lignocaine Hydrochloride Injection	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021
2	2	Tramadol Hydrochloride Injection	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021
3	3	Calcium Gluconate Injection	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021
4	4	Albendazole Oral Suspension	Form 25	25/31/89	NA	NA	22/11/2000	31/12/2021	04.03.17	31/12/2021
5	5	Ampicillin and Cloxacillin Injection	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021

Milky Bala
19/01/19

Bhaskar
19-01-2019

Pranav
19.01.19

5	6	Cefotaxime Sodium Injection	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021
7	8	Meropenem Injection	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021
8	9	Chloroquine Phosphate Syrup	Form 25	25/31/89	NA	NA	22/11/2000	31/12/2021	04.03.17	31/12/2021
9	11	Ondansetron Hydrochloride Injection	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021
10	12	Ranitidine Tablets	Form 25	25/31/89	NA	NA	22/11/2000	31/12/2021	04.03.17	31/12/2021
11	18	Antacid Tablets	Form 25	25/31/89	NA	NA	22/11/2000	31/12/2021	04.03.17	31/12/2021
12	22	Calcium Tablets	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021
13	23	Atropine Injection	Form 28	28/17/79	NA	NA	09.05.79	31/12/2021	04.03.17	31/12/2021

Note:- Assisted in technical evaluation the basis of document provided by BMSICL checklist II, III, & IV. Provided checklist complied with due diligence and care. Inspite, some in advertent discrepancies could have been crept in humble request to all concern to bring to the notice indue time if any discrepancies are observed for rectification.

Atulya Padda
19/01/19

Dr. Kumar
19-01-2019

Dr. Pradeep
19.01.19